News & Topics

HOME > News & Topics > Research > FY 2021 > Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses (Kurosaki G, in JEM)

Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses (Kurosaki G, in JEM)

By designing an immune antigen targeting the core region of the spike protein RBD (Receptor Binding Domain), which is structurally conserved among SARS-related viruses, the research group of Ryo Shinnakasu, Tomohiro Kurosaki (Lymphocyte Differentiation, IFReC), and Shuhei Sakakibara (Immune Regulation, IFReC) succeeded in efficiently inducing neutralizing antibodies with broad efficacy.

figure1


Commentary(PDF)


Article​(External Link)


Contact:
Tomohiro Kurosaki

Kurosaki Lab(Lymphocyte Differentiation)

Tel+81-6-6879-4457
Mail kurosakiifrec.osaka-u.ac.jp

Archives

 
TOPに戻る